DelveInsight: Advanced Renal Cell Carcinoma Market to Grow Through 2034

The market for advanced renal cell carcinoma (RCC) is projected to experience sustained expansion through 2034, according to a market analysis by DelveInsight. Growth drivers identified include an increasing disease burden, broadening treatment options, and the growing adoption of combination therapies involving immunotherapy and targeted agents.

The report highlights that combinations of immunotherapy and tyrosine kinase inhibitors (IO-TKI) represent a significant market segment. Key successful combinations, such as nivolumab plus ipilimumab, pembrolizumab plus axitinib, and cabozantinib plus nivolumab, have become standard first-line treatments, generating substantial revenue.

Renal cell carcinoma represented a significant disease burden in 2025, with an estimated incidence rate of approximately 17.5 per 100,000 men and women annually. The disease is nearly twice as prevalent in men and most frequently diagnosed among individuals aged 65-74. Advanced RCC accounts for roughly 15-20% of all RCC cases, with 20-30% of patients presenting with metastatic disease at initial diagnosis.

DelveInsight's comprehensive report analyzes market dynamics, treatment patterns, and epidemiology across key regions including the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. The analysis aims to equip stakeholders such as pharmaceutical companies, investors, and healthcare professionals with actionable intelligence for strategic planning and research initiatives.